

Programme

February 15, 2000

12.15 *Lunch*

13.30 OPENING SYMPOSIUM

Chairs G. Gialdroni Grassi (*Pavia, Italy*)
J. Jardim (*Sao Paulo, Brazil*)
Learning from each other: international viewpoints of management
Standard practice in North America
L. Mandell (*Hamilton, Canada*)
Standard practice in Japan
S. Kohno (*Nagasaki, Japan*)
Standard practice in Europe
G. Huchon (*Paris, France*)
Standard practice in Latin America
G. Luna (*Buenos Aires, Argentina*)
Contributions from the audience

14.45 PLENARY LECTURE 1

Chair R. Wise (*Birmingham, U.K.*)
Global issues: antibiotic usage, resistance emergence and control. Including resistance to new drugs
D. Low (*Toronto, Canada*)

15.30 *Tea Break*

16.00 SYMPOSIUM 1

Chairs L. Allegra (*Milan, Italy*)
R. Wilson (*London, U.K.*)
AECB-1: basic concepts of a heterogeneous disease
Bacteria from adherence to invasion: effects on disease progression
S. Hill (*Birmingham, U.K.*)
Standard versus new antibiotics: novel outcomes in clinical trial design
R. Wilson (*London, U.K.*)
Bacterial eradication, suppression, sequestration or dormancy?
S. Sethi (*Buffalo, NY, U.S.A.*)
Does any of this matter?: a family practice view
B. Holmes (*Nottingham, U.K.*)
Does any of this matter?: a managed care view
J. Sbarbaro (*Denver, CO, U.S.A.*)

17.30 PLENARY LECTURE 2

Chairs S. Kohno (*Nagasaki, Japan*)
D. Bassetti (*Genoa, Italy*)
Macro-aza-ketolides in RTI therapy: antibacterial and anti-inflammatory effects
H. Kobayashi (*Tokyo, Japan*)

February 16, 2000

08.30 SYMPOSIUM 2

Chairs L. Mandell (*Hamilton, Canada*)
A. Torres Marti (*Barcelona, Spain*)
Nosocomial and ventilator associated pneumonia: current controversies
The bacteriology of ventilator associated pneumonia
J. Chastre (*Paris, France*)
Perspectives on monotherapy, combination and rotation
H. Lode (*Berlin, Germany*)
Mini-Debate: do invasive diagnostic procedures affect the outcome of VAP
M. Niederman (*New York, NY, U.S.A.*) vs.
J. Y. Fagon (*Paris, France*)
Nosocomial pneumonia old and emerging concepts for prevention
D. Craven (*Boston, MA, U.S.A.*)

10.00 *Coffee Break*

10.30 PLENARY LECTURE 3

Chairs J. Garau (*Barcelona, Spain*)
A. Mistretta (*Catania, Italy*)
Cost effective management of community RTIs: evidence-based realities vs. experience-based empiricism plus cost-efficacy considerations
M. Niederman (*New York, NY, U.S.A.*)

11.00 DEBATE

Chairs T. File (*Akron, OH, U.S.A.*)
P. Ball (*Fife, U.K.*)
Treatment of RTI: a need for change?
Introduction: An environment for change?
T. File (*Akron, OH, U.S.A.*)
P. Ball (*Fife, U.K.*)

Primary care practice—a prescription for antimicrobial resistance?
Debating the controversy of appropriate antibiotic prescribing
(1) Evidence supporting the reservation of newer, more potent agents for severe infections and treatment failures only
J. Garau (*Barcelona, Spain*)
(2) Resistance necessitates change
T. File (*Akron, OH, U.S.A.*)
Open Discussion
(3) The real cost of antibiotic choices
P. Davey (*Fife, U.K.*)

Changing prescribing habits—are current initiatives working?

(1) Have guidelines influenced outcomes/resistance
E. Rubinstein (*Tel-Hashomer, Israel*)

A.4 ABSTRACTS

- (2) The implementation and effects of changes in antibiotic consumption pattern
O. Cars (*Uppsala, Sweden*)
Proven strategies for change: behavioural models
S. Johnson (*West Kingston, RI, U.S.A.*)
Defining the way forward—method and means
T. File (*Akron, OH, U.S.A.*)
P. Ball (*Fife, U.K.*)

12.30 Lunch

February 16, 2000

13.30 SYMPOSIUM 3

- Chairs Y. Niki (*Kawasaki, Japan*)
P. Ball (*Fife, U.K.*)
AECB-2: practical management
New antibacterials for AECB: Japanese experience
Y. Niki (*Kawasaki, Japan*)
New antibacterials for AECB: Western experience
V. T. Andriole (*New Haven, CT, U.S.A.*)
Clinical applicability of pharmacodynamics in AECB
J. Schentag (*Buffalo, NY, U.S.A.*)
Management options: reactive, cyclical pulse, sequential, long-term
R. Wilson (*London, U.K.*)
Management options: non antibacterial agents
R. Stockley (*Birmingham, U.K.*)

15.15 Tea Break

15.45 SYMPOSIUM 4

- Chairs N. Hoiby (*Copenhagen, Denmark*)
H. Kobayashi (*Tokyo, Japan*)
Cystic fibrosis, bronchiectasis and diffuse pan-bronchiolitis
Inter-relationships with diffuse pan-bronchiolitis
J.-I. Kadota (*Nagasaki, Japan*)
Changing microbiology: impact on outcomes and infection control
N. Hoiby (*Copenhagen, Denmark*)
Gene therapy
P. Squiban (*Strasbourg, France*)
Management of the older surviving patient
E. Pozzi (*Turin, Italy*)

17.15 PLENARY LECTURE 4

- Chair A. Torres Marti (*Barcelona, Spain*)
New treatment options in community acquired pneumonia
D. Campbell (*Shreveport, LA, U.S.A.*)

February 17, 2000

08.30 SYMPOSIUM 5

- Chairs G. C. Schito (*Genoa, Italy*)
H. Lode (*Berlin, Germany*)
Community acquired pneumonia-I: management turning points
Spread and implications of DRSP
K. Klugman (*Johannesburg, South Africa*)
Do current diagnostic techniques allow directed therapy?
T. File (*Akron, OH, U.S.A.*)

Can PCR and molecular techniques replace the microbiologist?

J. Verhoef (*Utrecht, The Netherlands*)

Optimal IV-oral switch therapy

J. Ramirez (*Louisville, KY, U.S.A.*)

Severe CAP: changing aetiology, patients and therapy

A. Torres Marti (*Barcelona, Spain*)

10.30 Coffee Break

11.00 SYMPOSIUM 6

Chairs R. Wise (*Birmingham, U.K.*)

E. Rubinstein (*Tel-Hashomer, Israel*)

Community acquired pneumonia-2: specific approaches

Influenza: progress in prophylaxis and treatment
P. Gross (*Ridgewood, NJ, U.S.A.*)

Chlamydomphila pneumoniae: how many roles
F. Blasi (*Milan, Italy*)

Fluoroquinolone pharmacodynamics: a paradigm for the future?

S. Zinner (*Cambridge, MA, U.S.A.*)

Will fluoroquinolones succeed when other agents fail?

E. Rubinstein (*Tel-Hashomer, Israel*)

12.30 Lunch

13.30 PLENARY LECTURE 5

Chair F. Paradisi (*Florence, Italy*)

Adverse reactions of respiratory antibacterials

Risk benefit and regulatory issues
P. Ball (*Fife, U.K.*)

14.00 ROUND TABLE

Chairs C. Grassi (*Pavia, Italy*)
R. Wilson (*London, U.K.*)

Harmonizing AECB guidelines

Guidelines compared:
ERS Task Force (1998)

M. Woodhead (*Manchester, U.K.*)

ATS view

Canadian view

M. Balter (*Toronto, Canada*)

Latin America

J. Jardim (*Sao Paulo, Brazil*)

Japanese Experience

Y. Niki (*Kawasaki, Japan*)

Discussion

Have guidelines impacted on clinical practice?
R. Grossman (*Toronto, Canada*)

Severity predictors: short and long-term
L. Allegra (*Milan, Italy*)

Can severity be classified?

M. Miravittles (*Barcelona, Spain*)

Discussion

Treatment decision factors: clinical or bacteriological

J. C. Pechere (*Geneva, Switzerland*)

Assessment of outcomes

P. W. Jones (*London U.K.*)